3 Top Growth Stocks With High Insider Ownership On KRX

Over the last 7 days, the South Korean market has dropped 3.1%, while the Healthcare sector has gained 3.4%. Despite a flat overall performance in the past year, earnings are expected to grow by 28% per annum over the next few years. In this environment, growth companies with high insider ownership can be particularly attractive as they often indicate confidence from those closest to the business and potential for significant returns.

Top 10 Growth Companies With High Insider Ownership In South Korea

Name	Insider Ownership	Earnings Growth
People & Technology (KOSDAQ:A137400)	16.5%	35%
Fine M-TecLTD (KOSDAQ:A441270)	17.2%	36.4%
Bioneer (KOSDAQ:A064550)	17.5%	89.7%
Global Tax Free (KOSDAQ:A204620)	18.1%	90.6%
Seojin SystemLtd (KOSDAQ:A178320)	29.6%	58.7%
Park Systems (KOSDAQ:A140860)	33%	36.6%
Vuno (KOSDAQ:A338220)	19.5%	105%
HANA Micron (KOSDAQ:A067310)	20%	97.4%
UTI (KOSDAQ:A179900)	33.1%	122.7%
Techwing (KOSDAQ:A089030)	18.7%	77.8%

Click here to see the full list of 86 stocks from our Fast Growing KRX Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

Seegene (KOSDAQ:A096530)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Seegene, Inc. manufactures and sells molecular diagnostics products worldwide and has a market cap of ₩1.34 trillion.

Operations: The company's revenue primarily comes from its Diagnostic Kits and Equipment segment, which generated ₩367.27 billion.

Insider Ownership: 35.7%

Return On Equity Forecast: N/A (2027 estimate)

Seegene is forecast to become profitable over the next 3 years, with earnings expected to grow 129.15% annually. Despite a recent net loss of KRW 2.08 million in Q1 2024, revenue is projected to grow at 13.1% per year, outpacing the South Korean market average of 10%. The company trades at good value compared to peers and has extended its buyback plan until July 2025, indicating confidence in its future growth potential.

• Click to explore a detailed breakdown of our findings in Seegene's earnings growth report.
• Our valuation report here indicates Seegene may be undervalued.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc., a biotech firm, specializes in creating long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars with a market cap of ₩16.04 billion.

Operations: Revenue from biotechnology amounts to ₩121.09 million.

Insider Ownership: 26.6%

Return On Equity Forecast: 45% (2027 estimate)

ALTEOGEN's earnings are forecast to grow at 72.95% annually, significantly outpacing the South Korean market average of 28%. The company recently became profitable and is trading at 72.3% below its estimated fair value. Its revenue is expected to grow by 48.7% per year, driven by the recent MFDS approval of Tergase®, a high-purity recombinant hyaluronidase with broad medical applications, marking a milestone in its transition to a commercial-stage company.

• Click here to discover the nuances of ALTEOGEN with our detailed analytical future growth report.
• According our valuation report, there's an indication that ALTEOGEN's share price might be on the expensive side.

CLASSYS (KOSDAQ:A214150)

Simply Wall St Growth Rating: ★★★★★☆

Overview: CLASSYS Inc. is a global provider of medical aesthetics devices with a market cap of ₩3.20 billion.

Operations: The company generates revenue primarily from its Surgical & Medical Equipment segment, which amounts to ₩191.53 billion.

Insider Ownership: 10.1%

Return On Equity Forecast: 28% (2027 estimate)

CLASSYS Inc. has demonstrated strong earnings growth, averaging 25.9% annually over the past five years, and is trading at 25.5% below its estimated fair value. Revenue is forecast to grow at 21.2% per year, outpacing the South Korean market average of 10%. Despite slower expected profit growth compared to the market (22.8% vs. 28%), CLASSYS's return on equity is projected to be high at 28.4% in three years, reflecting robust financial health and potential for sustained growth.

• Navigate through the intricacies of CLASSYS with our comprehensive analyst estimates report here.
• Our expertly prepared valuation report CLASSYS implies its share price may be too high.

Summing It All Up

• Delve into our full catalog of 86 Fast Growing KRX Companies With High Insider Ownership here.
• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com